BEDFORD, Mass., May 15, 2014 /PRNewswire/ -- Hologic, Inc.
(Hologic or the Company) (NASDAQ: HOLX), a leading developer,
manufacturer and supplier of premium diagnostic products, medical
imaging systems and surgical products, with an emphasis on serving
the healthcare needs of women, today announced that its new Tomcat
instrument will be showcased at the 114th General
Meeting of the American Society for Microbiology (asm2014) at the
Boston Convention and Exhibit Center, in Boston, Massachusetts from May 17 - 20th. The Tomcat instrument
is a fully automated general purpose platform designed to ease the
strain of pre-analytical sample processing by eliminating the
inefficient and error-prone activities required to manually aliquot
samples. The Company expects to begin commercial shipments of the
Tomcat instrument in June 2014.
"The full automation of Hologic's Tomcat instrument eases the
burden of manual sample transfer steps and helps low- to
high-volume laboratories streamline workflow and enhance
productivity," said Rohan Hastie,
PhD, Hologic's Division President, Diagnostics. "Adding our Tomcat
instrument to the Company's family of molecular testing systems
extends our commitment to give customers more freedom and control
over their workflow."
The design of Hologic's Tomcat instrument incorporates Lean
principles to deliver increased value through automation. The
Tomcat instrument performs a full range of sample processing
activities for liquid-based cytology samples - from de-capping and
capping of sample tubes, to vortexing, aliquoting, incubating, and
racking of each sample. The instrument also provides positive
barcode matching for each sample as well as reagent addition if
desired. By eliminating repetitive manual steps, the Tomcat
instrument can help laboratories reduce hands-on time and enhance
workflow efficiency while improving the quality of each result.
Featuring a standardized aliquoting process, the Tomcat
instrument accommodates multiple sample types concurrently, with
the ability to continuously load and unload samples and
consumables. The instrument is designed to minimize the risk of
cross-contamination, with limited hands-on interactions and an
intuitive touchscreen interface.
The Tomcat instrument is the latest addition to Hologic's family
of automated molecular testing systems which include: the Panther
system, a random and continuous access, fully automated molecular
testing platform designed with the flexibility to handle a wide
range of testing needs, and the Tigris system, the first fully
automated, high-throughput molecular testing system for large
laboratories.
The Tomcat instrument and the Panther system will be on display
at Hologic's booth #901 at the asm2014 General Meeting. For more
information about Hologic's molecular diagnostic technology, please
visit www.hologic.com or www.gen-probe.com.
About Hologic, Inc.:
Hologic, Inc. is a leading developer, manufacturer and supplier
of premium diagnostic products, medical imaging systems and
surgical products, with an emphasis on serving the healthcare needs
of women. The Company operates four core business units focused on
breast health, diagnostics, GYN surgical and skeletal health. With
a comprehensive suite of technologies and a robust research and
development program, Hologic is committed to improving lives. The
Company is headquartered in Massachusetts.
Hologic, Panther, Tigris, Tomcat and associated logos are
trademarks and/or registered trademarks of Hologic, Inc., and/or
its subsidiaries in the United
States and/or other countries.
Forward-looking Statement Disclaimer:
This News Release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic's molecular diagnostic products. There can be no
assurance these products will achieve the benefits described herein
and that such benefits will be replicated in any particular manner
with respect to an individual patient as the actual effect of the
use of the products can only be determined on a case-by-case basis
depending on the particular circumstances and patient in question.
Hologic expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any such statements
presented herein to reflect any change in expectations or any
change in events, conditions or circumstances on which any such
data or statements are based.
Contacts:
|
|
|
|
Marianne
McMorrow
|
Jim Culley
|
Manager, Corporate
Communications
|
Senior Director,
Corporate Communications
|
Tel: +1
781.999.7723
|
Tel: +1
781.999.7583
|
marianne.mcorrow@hologic.com
|
jim.culley@hologic.com
|
SOURCE Hologic, Inc.